19000 Investors following Orchid Chemical. Share this News with them.
0
Like this story, share it with millions of investors on M3
Orchid Chem launching 3 products in US this year
Orchid Chemicals & Pharmaceuticals will launch three drugs in the US market this year. Thanks mainly to this, the company expects a 25 per cent jump in its revenues for the current year, Orchid Chemicals’ Managing Director, Mr K Raghavendra Rao, told Business Line on Monday.
Orchid Chemicals & Pharmaceuticals will launch three drugs in the US market this year. Thanks mainly to this, the company expects a 25 per cent jump in its revenues for the current year, Orchid Chemicals' Managing Director, Mr K Raghavendra Rao, told Business Line on Monday. (Last year, the company's turnover was Rs 934 crore.)
The three drugs are: Cefepime and Cefdinir in the Cephalosporin range and Tazobactum-Piperaillin in the penicillin range.
Giving a calendar for growth, Mr Rao said that in 2007-08, growth would be fuelled by these three products. The addressable market for these three products is $1.5 billion (Rs 6,000 crore).
In 2008-09, Orchid would launch a few antibiotic drugs in the 'carbopenam range', he said. In addition, the company would begin marketing all the cephalosporin-based antibiotics in the European markets. The company has about a dozen products in that range. Further, it would launch a cephalosporin-based veterinary injectible in the US.
The year 2009-10 would see "another step function jump" because of launch of another clutch of carbopenams and a range of non-antibiotic products in the US. This is significant because under a 'first to file' law, Orchid would get a six-month market exclusivity for several of these products.
Further in 2009-10, Orchid would enter the Japanese market, which according to Mr Rao is lucrative because the prices there are government-fixed, but comfortably high.
The three drugs are: Cefepime and Cefdinir in the Cephalosporin range and Tazobactum-Piperaillin in the penicillin range. 
